Please use this identifier to cite or link to this item:
Title: Prostate cancer biomarkers: are we hitting the mark?
Austin Authors: McGrath, Shannon ;Christidis, Daniel;Perera, Marlon ;Hong, Sung Kyu;Manning, Todd G ;Vela, Ian;Lawrentschuk, Nathan
Affiliation: Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
Department of Urology, Seoul National University Bundang Hospital, Seoul, South Korea
Department of Urology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
Queensland University of Technology, Australian Prostate Cancer Research Center-Queensland, Brisbane, Australia
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Issue Date: Dec-2016 2016-12
Publication information: Prostate International 2016; 4(4): 130-135
Abstract: PURPOSE: Localised prostate cancer diagnosis and management is increasingly complex due to its heterogeneous progression and prognostic subgroups. Pitfalls in current screening and diagnosis have prompted the search for accurate and invasive molecular and genetic biomarkers for prostate cancer. Such tools may be able to distinguish clinically significant cancers from less aggressive variants to assist with prostate cancer risk stratification and guide decisions and healthcare algorithms. We aimed to provide a comprehensive review of the current prostate cancer biomarkers available and in development. METHODS: MEDLINE and EMBASE databases searches were conducted to identify articles pertaining to the use of novel biomarkers for prostate cancer. RESULTS: A growing number of novel biomarkers are currently under investigation. Such markers include urinary biomarkers, serology-based markers or pathological tissue assessments of molecular and genetic markers. While limited clinical data is present for analysis, early results appear promising. Specifically, a combination of serum and urinary biomarkers (Serum PSA + Urinary PCA3 + Urinary TMPRSS2-ERG fusion) appears to provide superior sensitivity and specificity profiles compared to traditional diagnostic approaches (AUC 0.88). CONCLUSION: The accurate diagnosis and risk stratification of prostate cancer is critical to ensure appropriate intervention. The development of non-invasive biomarkers can add to the information provided by current screening practices and allows for individualised risk stratification of patients. The use of these biomarkers appears to increase the sensitivity and specificity of diagnosis of prostate cancer. Further studies are necessary to define the appropriate use and time points of each biomarker and their effect on the management algorithm of prostate cancer.
DOI: 10.1016/j.prnil.2016.07.002
ORCID: 0000-0001-8553-5618
Journal: Prostate International
PubMed URL:
Type: Journal Article
Subjects: Biomarker
Prostate cancer
Prostate specific antigen
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jan 30, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.